NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment market size is expected to reach, USD 153.5 Billion in 2024, at a CAGR of 6.3% from 2018 to 2024. Factors propelling the growth of the market include growing number of inflammatory diseases, and advancement in drug development and therapies for treatment of immune-mediated inflammatory diseases. Moreover, increasing adoption of anti-inflammatory drugs, growing awareness among people coupled with government initiatives towards its treatment is further boosting the growth of the global immune-mediated inflammatory diseases treatment market.
The report segments the immune-mediated inflammatory diseases treatment market by Types of Diseases (asthma, chronic obstructive pulmonary diseases (COPD), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, heart disease, and others), by Types of Drugs (corticosteroids, non-steroidal anti-inflammatory drugs, anti-TNF-α agents, and others), by Therapies (targeted biologic therapies, novel therapies, and others) by End-User (hospitals, pharmacy store, and online pharmacy) and by Region (North America, Latin America, Europe, Asia-Pacific , and Middle East and Africa). The report studies the global immune-mediated inflammatory diseases treatment market over the forecast period (2018-2024).
The immune-mediated inflammatory diseases are chronic conditions causing severe tissue damage and disability. Immune-mediated inflammatory diseases (IMIDs) are medical disorders, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (IBD), behcet's disease, arthritis, and allergy. In severe cases, IMIDs can cause organ damage and are associated with increased mortality or morbidity.
Browse full research report with TOC on “Global Immune-Mediated Inflammatory Diseases Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at: https://www.energiasmarketresearch.com/global-immune-mediated-inflammatory-diseases-treatment-market-outlook/
To purchase report: sales@energiasmarketresearch.com
Key Findings from Global Immune-Mediated Inflammatory Diseases Treatment Market
- On the basis of Types of Diseases , the rheumatoid arthritis (RA) segment holds the largest share of the global immune-mediated inflammatory diseases treatment market in 2017 and is expected to grow at a significant growth rate during the forecast period due to growing number of elder people with chronic joints disorders, along with availability of biological therapeutic agents for the treatment
- Based on the Types of Drugs
- The anti-TNF-α agents segment holds the largest market share of the global IMIDs treatment market, due to the use of anti-TNF-α agents in various inflammatory conditions
- The non-steroidal anti-inflammatory drugs (NSAIDs) segment was the fastest growing segment of the global IMIDs treatment market in 2017, owing to growing number of people used NSAIDS for treatment of various inflammatory conditions
- Geographically, North America holds the major share of global IMIDs treatment market in 2017, owing to growing incidence and prevalence of IMIDs, and increasing number of IMIDs patients in the U.S., coupled with advancements in the treatment of immune-mediated inflammatory diseases
- Key players in Immune-Mediated Inflammatory Diseases Treatment Market are GlaxoSmithKline, Eli Lilly, AstraZeneca, Bristol-Myers, Sanofi, Enlivex Therapeutics Ltd, F-Hoffmann-La-Roche, Immune Pharmaceuticals, and Tanabe Pharma Corporation
Development in Targeted Biological Therapies and Immune Modulators Highly Effective in the Treatment of IMIDs
Immune-mediated inflammatory diseases (IMIDs), such as psoriasis, inflammatory bowel disease, rheumatoid arthritis, are chronic conditions affecting millions of people worldwide. Around 5% to 8% of the population in North America and Europe are affected by IMIDs. The growing awareness and understanding of the underlying pathogenesis and development in targeted biological therapies and immune modulators are the treatment options for many IMIDs. Various treatments available for IMIDs include systemic corticosteroids, immunosuppressant, biologic agents, and topical agents. Additionally, new clinical trials have provided strong evidence that targeted biological agent is highly effective and safer way to reduce inflammation and prevent tissue damage.
Global Immune-Mediated Inflammatory Diseases Treatment Market- Regional Insight
Geographically, the global immune-mediated inflammatory diseases treatment market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East and Africa. North America holds the major share of the global IMIDs market, owing to growing number of IMIDs patients, and growing research and development activity on targeted biological therapies. Growth of IMIDs treatment market in Europe is mainly owing to growing awareness about its treatment coupled with availability of various treatment options in this region.
About Energias Market Research Pvt. Ltd. -
Energias Market Research Pvt. Ltd. publishes high quality reports, in-depth market research studies, to help clients obtain investment level clarity on current business scenario, trends and segmentation for their future developments. We are committed to our client’s needs, by providing high quality custom reports solutions best fit for strategy development and implementation to high return of invest (RoI). We believe that exceptional problems need expertise to solve, and with the help of our industries expertise we are able to offer an in depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that includes energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.
Contact:
Alan Andrews
Business Development Manager
Phone - +1-716-239-4915
For any queries email us: info@energiasmarketresearch.com
To purchase report: sales@energiasmarketresearch.com